New Oral Anticoagulants (NOAC) in Stroke Patients (NOACISPLongTer)

University Hospital Basel

Status: Completed

Conditions: Atrial Fibrillation; Stroke

Treatments: Other: treatment with NOACs or VKAs

Study type: Observational

Funder types: Other

Identifiers

NCT03826927

PB_2016-00662 me14Engelter2;

Details and patient eligibility

About

Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world" setting at a stroke centre.

Full description

Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world" setting at a stroke centre. Special interest is payed to conditions not or only in part investigated in the large randomised controlled Trials (RCT) and that are specific to patients with cerebrovascular disease. This includes early start of NOAC treatment after recent stroke, very old patients, multimorbidity, patients with a history of intracranial haemorrhage (ICH) and patient satisfaction and preferences with VKA/NOACS.

Enrollment: 1,023 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• signed informed consent form (ICF)
• existing or newly diagnosed AF
• recent (< 3 month) stroke (ischemic or haemorrhagic) or TIA (=index event)
• treatment with NOACs or VKAs is continued, changed or initiated for prevention of ischemic events

Exclusion criteria

• patients not able or unwilling to sign ICF
• patient is, in the opinion of the investigator, unlikely to comply with the scheduled follow-up visits or is unsuitable for any other reason
• patients who will not be anticoagulated

Trial design

1,023 participants in 1 patient group

AF and cerebrovascular event

Description:

patients with AF and recent (\< 3 month) stroke or transient ischaemic attack (TIA) or intracranial haemorrhage (ICH) with or without pre-existing oral anticoagulation, in whom treatment with NOACs or VKAs is initiated or continued for prevention of ischemic events

Treatment:

Other: treatment with NOACs or VKAs